EP Patent

EP3626291A1 — Needle shield grip device

Assigned to Regeneron Pharmaceuticals Inc · Expires 2020-03-25 · 6y expired

What this patent protects

A needle guard grip device may include a body extending from a first end to a second end along a central longitudinal axis of the body. The body may include a plurality of ribs extending perpendicularly to the central longitudinal axis. The plurality of ribs may include a first s…

USPTO Abstract

A needle guard grip device may include a body extending from a first end to a second end along a central longitudinal axis of the body. The body may include a plurality of ribs extending perpendicularly to the central longitudinal axis. The plurality of ribs may include a first set of longitudinally spaced ribs disposed on a first side of the central longitudinal axis, and a second set of longitudinally spaced ribs disposed on a second side of the central longitudinal axis that is opposite of the first side. Moving along the central longitudinal axis, ribs of the first set of longitudinally spaced ribs may alternate with ribs of the second set of longitudinally spaced ribs. The body may include an interior cavity extending from an opening in the first end of the body to a wall extending perpendicularly to the central longitudinal axis. One rib of the plurality of ribs may be positioned closer to the second end of the body than the wall. A first rib of the first set of longitudinally spaced ribs may include a convex external surface, and a second rib of the first set of longitudinal spaced ribs may include a concave external surface. Additionally, a retainer may be disposed within the interior cavity and may have a tab extending from a portion of the retainer closest to the first end of the body. The tab may extend toward the central longitudinal axis and at an angle to the central longitudinal axis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3626291A1
Jurisdiction
EP
Classification
Expires
2020-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Regeneron Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.